183 related articles for article (PubMed ID: 24314137)
41. Computer Aided Drug Design Approaches for Identification of Novel Autotaxin (ATX) Inhibitors.
Vrontaki E; Melagraki G; Kaffe E; Mavromoustakos T; Kokotos G; Aidinis V; Afantitis A
Curr Med Chem; 2016; 23(17):1708-24. PubMed ID: 26997151
[TBL] [Abstract][Full Text] [Related]
42. Autotaxin inhibitors: a patent review.
Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
[TBL] [Abstract][Full Text] [Related]
43. Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model.
Lei H; Cao Z; Wu H; Li T; Wang X; Chen Y; Ma E; Sun L; Zhai X
Eur J Med Chem; 2022 Jan; 227():113951. PubMed ID: 34742015
[TBL] [Abstract][Full Text] [Related]
44. Hybrid imidazo[1,2-a]pyridine analogs as potent ATX inhibitors with concrete in vivo antifibrosis effect.
Li T; Lei H; Yang J; Cao Z; Yang Y; Liu Z; Sun R; Yang X; Zhai X
Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200171. PubMed ID: 35661405
[TBL] [Abstract][Full Text] [Related]
45. alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors.
Cui P; McCalmont WF; Tomsig JL; Lynch KR; Macdonald TL
Bioorg Med Chem; 2008 Mar; 16(5):2212-25. PubMed ID: 18082408
[TBL] [Abstract][Full Text] [Related]
46. Structural snapshots of the catalytic cycle of the phosphodiesterase Autotaxin.
Hausmann J; Keune WJ; Hipgrave Ederveen AL; van Zeijl L; Joosten RP; Perrakis A
J Struct Biol; 2016 Aug; 195(2):199-206. PubMed ID: 27268273
[TBL] [Abstract][Full Text] [Related]
47. The Bulk of Autotaxin Activity Is Dispensable for Adult Mouse Life.
Katsifa A; Kaffe E; Nikolaidou-Katsaridou N; Economides AN; Newbigging S; McKerlie C; Aidinis V
PLoS One; 2015; 10(11):e0143083. PubMed ID: 26569406
[TBL] [Abstract][Full Text] [Related]
48. Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).
Sun Y; Zhang W; Evans JF; Floreani A; Zou Z; Nishio Y; Qi R; Leung PS; Bowlus CL; Gershwin ME
Autoimmun Rev; 2016 Aug; 15(8):795-800. PubMed ID: 27019050
[TBL] [Abstract][Full Text] [Related]
49. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
50. The Structural Binding Mode of the Four Autotaxin Inhibitor Types that Differentially Affect Catalytic and Non-Catalytic Functions.
Salgado-Polo F; Perrakis A
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623219
[TBL] [Abstract][Full Text] [Related]
51. A 3D view of autotaxin.
Nishimasu H; Ishitani R; Aoki J; Nureki O
Trends Pharmacol Sci; 2012 Mar; 33(3):138-45. PubMed ID: 22277299
[TBL] [Abstract][Full Text] [Related]
52. Autotaxin regulates vascular development via multiple lysophosphatidic acid (LPA) receptors in zebrafish.
Yukiura H; Hama K; Nakanaga K; Tanaka M; Asaoka Y; Okudaira S; Arima N; Inoue A; Hashimoto T; Arai H; Kawahara A; Nishina H; Aoki J
J Biol Chem; 2011 Dec; 286(51):43972-43983. PubMed ID: 21971049
[TBL] [Abstract][Full Text] [Related]
53. The Expression Regulation and Biological Function of Autotaxin.
Zhang X; Li M; Yin N; Zhang J
Cells; 2021 Apr; 10(4):. PubMed ID: 33921676
[TBL] [Abstract][Full Text] [Related]
54. Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.
Banerjee S; Norman DD; Lee SC; Parrill AL; Pham TC; Baker DL; Tigyi GJ; Miller DD
J Med Chem; 2017 Feb; 60(4):1309-1324. PubMed ID: 28112925
[TBL] [Abstract][Full Text] [Related]
55. Secretion and lysophospholipase D activity of autotaxin by adipocytes are controlled by N-glycosylation and signal peptidase.
Pradère JP; Tarnus E; Grès S; Valet P; Saulnier-Blache JS
Biochim Biophys Acta; 2007 Jan; 1771(1):93-102. PubMed ID: 17208043
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
Federico L; Pamuklar Z; Smyth SS; Morris AJ
Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
[TBL] [Abstract][Full Text] [Related]
58. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer.
Barbayianni E; Kaffe E; Aidinis V; Kokotos G
Prog Lipid Res; 2015 Apr; 58():76-96. PubMed ID: 25704398
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.
van Meeteren LA; Ruurs P; Christodoulou E; Goding JW; Takakusa H; Kikuchi K; Perrakis A; Nagano T; Moolenaar WH
J Biol Chem; 2005 Jun; 280(22):21155-61. PubMed ID: 15769751
[TBL] [Abstract][Full Text] [Related]
60. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.
Saunders LP; Ouellette A; Bandle R; Chang WC; Zhou H; Misra RN; De La Cruz EM; Braddock DT
Mol Cancer Ther; 2008 Oct; 7(10):3352-62. PubMed ID: 18852138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
